Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1626gms

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 5	FEB 05	German (DE) application and patent publication number format changes
NEWS 6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8	MAR 03	FRANCEPAT now available on STN
NEWS 9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10	MAR 29	WPIFV now available on STN
NEWS 11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 12	APR 26	PROMT: New display field available
NEWS 13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 14	APR 26	LITALERT now available on STN
NEWS 15	APR 27	NLDB: New search and display fields available
NEWS 16	May 10	PROUSDDR now available on STN
NEWS 17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS 18	May 12	EXTEND option available in structure searching
NEWS 19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 20	May 17	FRFULL now available on STN
NEWS 21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS 22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 23	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 24	May 27	Explore APOLLIT with free connect time in June 2004

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:28:16 ON 15 JUN 2004

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:28:47 ON 15 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4
DICTIONARY FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10684233.str



chain nodes :
10 11 12 13 14 15 16 17 18 25
ring nodes :
1 2 3 4 5 6 7 8 9 19 20 21 22 23 24
chain bonds :
3-14 9-10 10-11 10-13 11-12 14-15 15-16 16-17 17-18 18-23 18-25
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-8 8-9 19-20 19-24 20-21 21-22 22-23
23-24
exact/norm bonds :
5-6 5-9 10-11 10-13 11-12 15-16 16-17 18-25
exact bonds :
3-14 7-8 8-9 9-10 14-15 17-18 18-23
normalized bonds :
1-2 1-6 2-3 3-4 4-7 6-7 19-20 19-24 20-21 21-22 22-23 23-24
isolated ring systems :
containing 1 : 19 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 11:29:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     30 TO ITERATE

100.0% PROCESSED      30 ITERATIONS                                2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          272 TO      928
PROJECTED ANSWERS:               2 TO      124

L2             2 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 11:29:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    587 TO ITERATE

100.0% PROCESSED     587 ITERATIONS                              36 ANSWERS
SEARCH TIME: 00.00.01

L3            36 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             155.42     155.63

FILE 'CAPLUS' ENTERED AT 11:29:15 ON 15 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 15 Jun 2004 VOL 140 ISS 25
FILE LAST UPDATED: 14 Jun 2004 (20040614/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:333571 CAPLUS
DOCUMENT NUMBER: 140:321235
TITLE: Preparation of indolecarboxamides as β2 adrenergic receptor agonists
INVENTOR(S): Brown, Alan Daniel; Bryans, Justin Stephen; Bunnage, Mark Edward; Glossop, Paul Alan; Lane, Charlotte Alice Louise; Lewthwaite, Russell Andrew; Mantell, Simon John
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032921	A1	20040422	WO 2003-IB4441	20031006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1407769	A1	20040414	EP 2002-292513	20021011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: EP 2002-292513 A 20021011
EP 2003-290069 A 20030110

GI



I

AB Title compds. (I; n = 0-4; R1, R2 = H, alkyl; R3 = H, (un)substituted alkyl; R4-R8 = H, OH, alkyl, alkoxy, hydroxyalkyl, thioalkyl, halo, trifluoromethyl, benzyloxy; their pharmaceutical acceptable salts and/or isomers,tautomers, solvates or isotopic variations), were prepared as β2 adrenergic receptor agonists. Thus, 5-[(2R)-2-[[(2R)-2-[[tert-butyldimethylsilyl]oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1H-indole-2-carboxylic acid (preparation given) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, hydroxybenzotriazole, and 2-methoxybenzylamine were stirred 18 h in DMF to give the silyl-protected amide derivative This was stirred with NH4F in MeOH/H2O to give 5-[(2R)-2-[[(2R)-2-[[tert-butyldimethylsilyl]oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide. I showed a β2 cAMP EC50 = 0.02-4 nM. I are useful for treating inflammatory, allergic and respiratory diseases.

IT **679427-60-2P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-benzyloxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(β2 adrenergic receptor agonist; preparation of indolecarboxamides as β2 adrenergic receptor agonists)

RN 679427-60-2 CAPLUS

CN 1H-Indole-2-carboxamide, N-[[2,6-dimethoxy-4-(phenylmethoxy)phenyl]methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



IT **677026-80-1P 677026-81-2P 677026-82-3P**
677026-83-4P 677026-84-5P 679427-58-8P,
5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,4-dichlorobenzyl)-1H-indole-2-carboxamide
679427-59-9P, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(3-hydroxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-61-3P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-hydroxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-62-4P**
679427-63-5P, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-hydroxy-6-methoxybenzyl)-1H-indole-2-carboxamide **679427-64-6P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,6-difluorobenzyl)-1H-indole-2-carboxamide **679427-65-7P**,
5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-chlorobenzyl)-1H-indole-2-carboxamide **679427-66-8P**,
5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-fluorobenzyl)-1H-indole-2-carboxamide **679427-67-9P**,
5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-hydroxybenzyl)-1H-indole-2-carboxamide **679427-68-0P**
, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(3-hydroxybenzyl)-1H-indole-2-carboxamide **679427-69-1P**
, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-methylsulfanylbenzyl)-1H-indole-2-carboxamide
679427-70-4P, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-methylsulfanylbenzyl)-1H-indole-2-carboxamide **679427-71-5P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,3-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-72-6P**,
5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,4-dimethoxybenzyl)-1H-indole-2-carboxamide
679427-73-7P, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-ethoxybenzyl)-1H-indole-2-carboxamide **679427-74-8P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-benzyl-N-methyl-1H-indole-2-carboxamide **679427-75-9P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-benzyl-1H-indole-2-carboxamide **679427-76-0P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-fluorobenzyl)-1H-indole-2-carboxamide **679427-77-1P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-methoxy-3-methylbenzyl)-1H-indole-2-carboxamide **679427-78-2P**,
5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(3-methoxy-2-methylbenzyl)-1H-indole-2-carboxamide
679427-79-3P, 1-Ethyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-80-6P**, 1-Ethyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-methoxybenzyl)-

1H-indole-2-carboxamide **679427-81-7P**, 1-Ethyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-chlorobenzyl)-1H-indole-2-carboxamide **679427-82-8P**, 1-Methyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-83-9P**, 1-Methyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide **679427-84-0P**, 1-Methyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-chlorobenzyl)-1H-indole-2-carboxamide **679427-85-1P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide **679427-86-2P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-(2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-87-3P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-(2-ethoxybenzyl)-1H-indole-2-carboxamide **679427-88-4P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-benzyl-1H-indole-2-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(β2 adrenergic receptor agonist; preparation of indolecarboxamides as β2 adrenergic receptor agonists)

RN 677026-80-1 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677026-81-2 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—CF_3

RN 677026-82-3 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677026-83-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OMe

RN 677026-84-5 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[2-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-58-8 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2,4-dichlorophenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-59-9 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(3-hydroxy-2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-61-3 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(4-hydroxy-2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-62-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[[2-methoxy-6-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-63-5 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-hydroxy-6-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-64-6 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2,6-difluorophenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-65-7 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2-chlorophenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-66-8 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2-fluorophenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-67-9 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(4-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-68-0 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-69-1 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[[2-(methylthio)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-70-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[[4-(methylthio)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

SMe

RN 679427-71-5 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2,3-dimethoxyphenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OMe

RN 679427-72-6 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2,4-dimethoxyphenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



OMe

RN 679427-73-7 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2-ethoxyphenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-74-8 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-75-9 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-76-0 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(4-fluorophenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-77-1 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-methoxy-3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-78-2 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OMe

RN 679427-79-3 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2,6-dimethoxyphenyl)methyl]-1-ethyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-80-6 CAPLUS
CN 1H-Indole-2-carboxamide, 1-ethyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-methoxyphenyl)methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-81-7 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(4-chlorophenyl)methyl]-1-ethyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-82-8 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-83-9 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-84-0 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(4-chlorophenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1-methyl-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-85-1 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]butyl]-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-86-2 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-87-3 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2-ethoxyphenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 679427-88-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]butyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:305136 CAPLUS
DOCUMENT NUMBER: 140:303532
TITLE: Preparation of indolecarboxamides as β2 adrenergic receptor agonists
INVENTOR(S): Brown, Alan; Bryans, Justin; Bunnage, Mark Edward; Glossop, Paul Alan; Lane, Charlotte; Mantell, Simon
PATENT ASSIGNEE(S): Pfizer Limited, UK
SOURCE: Eur. Pat. Appl., 32 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1407769	A1	20040414	EP 2002-292513	20021011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO 2004032921	A1	20040422	WO 2003-IB4441	20031006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2002-292513 A 20021011
EP 2003-290069 A 20030110

OTHER SOURCE(S): MARPAT 140:303532

GI



I

AB Title compds. (I; n = 0-4; R1, R2 = H, alkyl; R3 = H, alkyl, hydroxyalkyl; R4-R8 = H, OH, alkyl, alkoxy, hydroxyalkyl, thioalkyl, halo, trihalomethyl), were prepared Thus, 5-[(2R)-2-[[(2R)-2-[[tert-butyldimethylsilyl]oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1H-indole-2-carboxylic acid (preparation given) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, hydroxybenzotriazole, and 2-methoxybenzylamine were stirred 18 h in DMF to give the silyl-protected amide derivative This was stirred with NH4F in MeOH/H2O to give 5-[(2R)-2-[[(2R)-2-[[tert-butyldimethylsilyl]oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide. I showed a β2 cAMP EC50 = 0.02-0.9 nM. The indole derivs. according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

IT **677026-80-1P 677026-81-2P 677026-82-3P**
677026-83-4P 677026-84-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of indolecarboxamides as β2 adrenergic receptor agonists)

RN 677026-80-1 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(2-methoxyphenyl)methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677026-81-2 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 677026-82-3 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(2,6-dimethoxyphenyl)methyl]-5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677026-83-4 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[(3-methoxyphenyl)methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OMe

RN 677026-84-5 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-[2-(3-methoxyphenyl)ethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.70	167.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.39	-1.39

FILE 'REGISTRY' ENTERED AT 11:32:32 ON 15 JUN 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4
DICTIONARY FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10684233a.str



chain nodes :
10 11 12 13 14 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
3-14 9-10 10-11 10-13 11-12 14-15 15-16 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-8 8-9
exact/norm bonds :
5-6 5-9 10-11 10-13 11-12 15-16 16-17
exact bonds :
3-14 7-8 8-9 9-10 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-7 6-7
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l5
SAMPLE SEARCH INITIATED 11:32:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     41 TO ITERATE

100.0% PROCESSED      41 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          436 TO     1204
PROJECTED ANSWERS:               4 TO      200

L6             4 SEA SSS SAM L5

=> s l5 sss full
FULL SEARCH INITIATED 11:32:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    892 TO ITERATE

100.0% PROCESSED     892 ITERATIONS                              49 ANSWERS
SEARCH TIME: 00.00.01

L7            49 SEA SSS FUL L5

=> FIL CAPLUS
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 155.42     322.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00      -1.39

FILE 'CAPLUS' ENTERED AT 11:32:59 ON 15 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Jun 2004  VOL 140 ISS 25
FILE LAST UPDATED: 14 Jun 2004  (20040614/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l7
L8             2 L7

=> d his
```

```
     (FILE 'HOME' ENTERED AT 11:28:16 ON 15 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 11:28:47 ON 15 JUN 2004
L1              STRUCTURE UPLOADED
L2            2 S L1
L3           36 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:29:15 ON 15 JUN 2004
L4            2 S L3

     FILE 'REGISTRY' ENTERED AT 11:32:32 ON 15 JUN 2004
L5              STRUCTURE UPLOADED
L6            4 S L5
L7           49 S L5 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:32:59 ON 15 JUN 2004
L8            2 S L7

=> d scan

L8    2 ANSWERS   CAPLUS  COPYRIGHT 2004 ACS on STN
IC    ICM  A61K031-40
      ICS  C07D209-42
CC    27-11 (Heterocyclic Compounds (One Hetero Atom))
      Section cross-reference(s): 1
TI    Preparation of indolecarboxamides as β2 adrenergic receptor agonists
ST    hydroxymethylphenylethylaminopropylindolecarboxamide prepn beta agonist;
      indolecarboxamide hydroxymethylphenylethylaminopropyl prepn beta agonist;
      asthma bronchitis emphysema obstructive airway disease treatment
      indolecarboxamide prepn; cns disorder pneumoconiosis bronchiectasis
      premature labor dementia treatment indolecarboxamide
IT    Respiratory distress syndrome
         (adult, treatment; preparation of indolecarboxamides as β2 adrenergic
         receptor agonists)
IT    Bronchi, disease
         (bronchiectasis, treatment; preparation of indolecarboxamides as β2
         adrenergic receptor agonists)
IT    Bronchi, disease
         (bronchitis, treatment; preparation of indolecarboxamides as β2
         adrenergic receptor agonists)
IT    Nervous system, disease
         (central, treatment; preparation of indolecarboxamides as β2 adrenergic
         receptor agonists)
IT    Lung, disease
         (chronic obstructive, treatment; preparation of indolecarboxamides as
         β2 adrenergic receptor agonists)
IT    Mental disorder
         (dementia, arteriosclerotic dementia treatment; preparation of
         indolecarboxamides as β2 adrenergic receptor agonists)
IT    Mental disorder
         (depression, treatment; preparation of indolecarboxamides as β2
         adrenergic receptor agonists)
IT    Learning
      Memory, biological
         (disorder, treatment; preparation of indolecarboxamides as β2
         adrenergic receptor agonists)
IT    Lung, disease
         (eosinophilia, chronic eosinophilic pneumonia, treatment; preparation of
         indolecarboxamides as β2 adrenergic receptor agonists)
IT    Heart, disease
```

(failure, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Respiratory tract, disease
(inflammation, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Respiratory tract, disease
(obstructive, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Parturition
(premature, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Anti-Alzheimer's agents
Anti-inflammatory agents
Antiasthmatics
Antidepressants
Antiparkinsonian agents
Cognition enhancers
Human
Nervous system agents
(preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Gastric acid
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reducers; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Nervous system, disease
(tardive dyskinesia, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Alzheimer's disease
Asthma
Dermatitis
Drug dependence
Emphysema
Glaucoma (disease)
Parkinson's disease
Pneumoconiosis
Psoriasis
(treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Digestive tract, disease
(ulcer, peptic, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Adrenoceptor agonists
(β2-; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT **677026-80-1P 677026-81-2P 677026-82-3P**
677026-83-4P 677026-84-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT 2039-67-0, 3-Methoxyphenethylamine 3300-51-4, 4-Trifluoromethylbenzylamine 3886-69-9 5071-96-5, 3-Methoxybenzylamine 6850-57-3, 2-Methoxybenzylamine 7254-19-5, 5-Bromo-1H-indole-2-carboxylic acid 17616-47-6, Isoprenylacetate 20781-22-0, 2,6-Dimethoxybenzylamine 160889-18-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT 210345-56-5P **677026-85-6P 677026-86-7P**
677026-87-8P 677026-88-9P 677026-89-0P

677026-90-3P 677026-91-4P 677026-92-5P 677026-93-6P 677026-94-7P
677026-95-8P 677026-96-9P 677026-97-0P 677026-98-1P 677026-99-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indolecarboxamides as β2 adrenergic receptor agonists)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 2 ANSWERS CAPLUS COPYRIGHT 2004 ACS on STN
IC ICM A61K031-40
ICS C07D209-42
CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63
TI Preparation of indolecarboxamides as β2 adrenergic receptor agonists
ST hydroxymethylphenylethylaminopropylindolecarboxamide prepn beta agonist; indolecarboxamide hydroxymethylphenylethylaminopropyl prepn beta agonist asthma; bronchitis bronchiectasis emphysema obstructive airway disease treatment indolecarboxamide prepn
IT Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E, atopic bronchial IgE-mediated asthma; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Respiratory distress syndrome
(adult, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
Asthma
(allergic, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Occupational diseases
(asthma, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Bronchi, disease
(bronchiectasis, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Bronchi, disease
(bronchiolitis, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Bronchi, disease
(bronchitis, treatment of acute; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Bronchi, disease
(bronchitis, treatment of infectious; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Bronchi
(bronchoconstriction, treatment of chronic or acute; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
(caused by environmental factors, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
(caused by pathophysiol. disturbances, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Bronchi, disease
(chronic bronchitis, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Lung, disease
(chronic obstructive, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Trachea (anatomical)

(disease, tracheobronchitis, treatment of acute laryngo-; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Breathing (animal)
(dyspnea, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Respiratory tract, disease
(hyperresponsiveness, associated with pulmonary hypertension, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Respiratory tract, disease
(inflammation, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Respiratory tract
(obstruction, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Respiratory tract, disease
(obstructive, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
(occupational, treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Allergy inhibitors
Antiasthmatics
Human
(preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Bronchi, disease
(tracheobronchitis, treatment of acute laryngo-; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
(treatment of cold-air induced; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
(treatment of emphysematous; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Pneumonia
(treatment of eosinophilic; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
(treatment of essential; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
(treatment of exercise-induced; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
(treatment of incipient; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
(treatment of infective; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
(treatment of non-allergic; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
(treatment of non-atopic; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Disease, animal
(treatment of wheezy infant; preparation of indolecarboxamides as β2 adrenergic receptor agonists)
IT Asthma
Asthma
Emphysema

Emphysema
(treatment; preparation of indolecarboxamides as β2 adrenergic receptor agonists)

IT Adrenoceptor agonists
(β-, β2 type; preparation of indolecarboxamides as β2 adrenergic receptor agonists)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β2; preparation of indolecarboxamides as β2 adrenergic receptor agonists)

IT 10500-08-0P, Acetic acid 1-methylenepropyl ester 65977-12-0P, Methyl 3-bromo-2,6-dimethoxybenzoate 90609-90-8P, 2-Methoxy-3-methylbenzamide 135329-22-5P, 3-Methoxy-2-methylbenzamide 145297-98-9P, 2-Hydroxy-6-methoxybenzamide 160825-78-5P, 4-Benzyloxy-2,6-dimethoxybenzylamine 210345-56-5P 623570-52-5P **677026-85-6P** **677026-86-7P** **677026-87-8P** **677026-88-9P** **677026-89-0P** 677026-90-3P 677026-91-4P 677026-92-5P 677026-93-6P 677026-94-7P 677026-95-8P 677026-96-9P 677026-97-0P 677026-98-1P 677026-99-2P **679427-89-5P**, 5-[(2R)-2-[[(2R)-2-[(tert-Butyldimethylsilyl)oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-(2,4-dichlorobenzyl)-1H-indole-2-carboxamide **679427-90-8P**, 5-[(2R)-2-[[(2R)-2-[(tert-Butyldimethylsilyl)oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-(3-benzyloxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-91-9P**, 5-[(2R)-2-[[(2R)-2-[(tert-Butyldimethylsilyl)oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-(3-hydroxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-92-0P**, 5-[(2R)-2-[[(2R)-2-[(tert-Butyldimethylsilyl)oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-(4-benzyloxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide 679427-93-1P, Ethyl 1-methyl-5-[(2R)-2-[((1R)-1-phenylethyl)amino]propyl]-1H-indole-2-carboxylate 679427-94-2P, Ethyl 1-methyl-5-((2R)-2-aminopropyl)-1H-indole-2-carboxylate 679427-95-3P, Ethyl 1-methyl-5-[(2R)-2-[[(2R)-2-[4-(benzyloxy)-3-(hydroxymethyl)phenyl]-2-[(tert-butyldimethylsilyl)oxy]ethyl]amino]propyl]-1H-indole-2-carboxylate 679427-96-4P, Ethyl 1-methyl-5-[(2R)-2-[[(2R)-2-[(tert-butyldimethylsilyl)oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1H-indole-2-carboxylate 679427-97-5P, 1-Methyl-5-[(2R)-2-[[(2R)-2-[(tert-butyldimethylsilyl)oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1H-indole-2-carboxylic acid 679427-98-6P, Ethyl 1-ethyl-5-[(2R)-2-[((1R)-1-phenylethyl)amino]propyl]-1H-indole-2-carboxylate 679427-99-7P, Ethyl 1-ethyl-5-((2R)-2-aminopropyl)-1H-indole-2-carboxylate 679428-00-3P, Ethyl 1-ethyl-5-[(2R)-2-[[(2R)-2-[4-(benzyloxy)-3-(hydroxymethyl)phenyl]-2-[(tert-butyldimethylsilyl)oxy]ethyl]amino]propyl]-1H-indole-2-carboxylate 679428-01-4P, Ethyl 1-ethyl-5-[(2R)-2-[[(2R)-2-[(tert-butyldimethylsilyl)oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1H-indole-2-carboxylate 679428-02-5P, 1-Ethyl-5-[(2R)-2-[[(2R)-2-[(tert-butyldimethylsilyl)oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1H-indole-2-carboxylic acid 679428-03-6P 679428-04-7P 679428-05-8P, Methyl 5-[(2R)-2-[((1R)-1-phenylethyl)amino]butyl]-1H-indole-2-carboxylate 679428-06-9P, Methyl 5-((2R)-2-aminobutyl)-1H-indole-2-carboxylate 679428-07-0P, Methyl 5-[(2R)-2-[[(2R)-2-[4-(benzyloxy)-3-(hydroxymethyl)phenyl]-2-[(tert-butyldimethylsilyl)oxy]ethyl]amino]butyl]-1H-indole-2-carboxylate 679428-08-1P, 5-[(2R)-2-[[(2R)-2-[4-(Benzyloxy)-3-(hydroxymethyl)phenyl]-2-(tert-butyldimethylsilyloxy)ethyl]amino]butyl]-1H-indole-2-carboxylic acid **679428-09-2P**, 5-[(2R)-2-[[(2R)-2-[4-(Benzyloxy)-3-(hydroxymethyl)phenyl]-2-[(tert-butyldimethylsilyl)oxy]ethyl]amino]butyl]-N-(4-chlorobenzyl)-1H-indole-2-carboxamide **679428-10-5P**,

5-[(2R)-2-[[(2R)-2-[4-(Benzyloxy)-3-(hydroxymethyl)phenyl]-2-[(tert-butyldimethylsilyl)oxy]ethyl]amino]butyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide **679428-11-6P**, 5-[(2R)-2-[[(2R)-2-[4-(Benzyloxy)-3-(hydroxymethyl)phenyl]-2-[(tert-butyldimethylsilyl)oxy]ethyl]amino]butyl]-N-(2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679428-12-7P**, 5-[(2R)-2-[[(2R)-2-[4-(Benzyloxy)-3-(hydroxymethyl)phenyl]-2-[(tert-butyldimethylsilyl)oxy]ethyl]amino]butyl]-N-(2-ethoxybenzyl)-1H-indole-2-carboxamide 679428-13-8P 679428-14-9P, 4-Benzyloxy-2,6-dimethoxybenzaldehyde 679428-15-0P, Allyl(4-benzyloxy-2,6-dimethoxybenzyl)amine 679428-16-1P, 2-Benzyloxy-6-methoxybenzamide 679428-17-2P, 6-Benzyloxy-2-methoxybenzylamine 679428-18-3P, Methyl 2,6-dimethoxy-3-hydroxybenzoate 679428-19-4P, Methyl 3-benzyloxy-2,6-dimethoxybenzoate 679428-20-7P, 3-Benzyloxy-2,6-dimethoxybenzoic acid 679428-21-8P, 3-Benzyloxy-2,6-dimethoxybenzamide 679428-22-9P, (3-Benzyloxy-2,6-dimethoxybenzyl)carbamic acid tert-butyl ester 679428-23-0P, 3-Benzyloxy-2,6-dimethoxybenzylamine hydrochloride 679428-24-1P 679428-25-2P 679428-26-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indolecarboxamides as β2 adrenergic receptor agonists)

IT 107-00-6, But-1-yne 107-11-9, Allylamine 2039-67-0, 3-Methoxyphenethylamine 3147-64-6, 2-Hydroxy-6-methoxybenzoic acid 3300-51-4, 4-Trifluoromethylbenzylamine 3886-69-9, (R)-α-Methylbenzylamine 5071-96-5, 3-Methoxybenzylamine 5419-55-6, Triisopropylborate 6850-57-3, 2-Methoxybenzylamine 7254-19-5, 5-Bromo-1H-indole-2-carboxylic acid 17616-47-6, Isoprenylacetate 20781-22-0, 2,6-Dimethoxybenzylamine 22080-96-2, 2,6-Dimethoxy-4-hydroxybenzaldehyde 26507-91-5, 2-Methoxy-3-methylbenzoic acid 55289-06-0, 3-Methoxy-2-methylbenzoic acid 69385-30-4, 2,6-Difluorobenzylamine 73219-89-3, 3-Bromo-2,6-dimethoxybenzoic acid 160889-18-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indolecarboxamides as β2 adrenergic receptor agonists)

IT **679427-60-2P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-benzyloxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(β2 adrenergic receptor agonist; preparation of indolecarboxamides as β2 adrenergic receptor agonists)

IT **677026-80-1P 677026-81-2P 677026-82-3P 677026-83-4P 677026-84-5P 679427-58-8P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,4-dichlorobenzyl)-1H-indole-2-carboxamide **679427-59-9P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(3-hydroxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-61-3P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-hydroxy-2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-62-4P 679427-63-5P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-hydroxy-6-methoxybenzyl)-1H-indole-2-carboxamide **679427-64-6P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,6-difluorobenzyl)-1H-indole-2-carboxamide **679427-65-7P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-chlorobenzyl)-1H-indole-2-carboxamide **679427-66-8P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-fluorobenzyl)-1H-indole-2-carboxamide **679427-67-9P**,

5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-hydroxybenzyl)-1H-indole-2-carboxamide **679427-68-0P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(3-hydroxybenzyl)-1H-indole-2-carboxamide **679427-69-1P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-methylsulfanylbenzyl)-1H-indole-2-carboxamide **679427-70-4P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-methylsulfanylbenzyl)-1H-indole-2-carboxamide **679427-71-5P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,3-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-72-6P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,4-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-73-7P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-ethoxybenzyl)-1H-indole-2-carboxamide **679427-74-8P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-benzyl-N-methyl-1H-indole-2-carboxamide **679427-75-9P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-benzyl-1H-indole-2-carboxamide **679427-76-0P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-fluorobenzyl)-1H-indole-2-carboxamide **679427-77-1P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-methoxy-3-methylbenzyl)-1H-indole-2-carboxamide **679427-78-2P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(3-methoxy-2-methylbenzyl)-1H-indole-2-carboxamide **679427-79-3P**, 1-Ethyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-80-6P**, 1-Ethyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide **679427-81-7P**, 1-Ethyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-chlorobenzyl)-1H-indole-2-carboxamide **679427-82-8P**, 1-Methyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-83-9P**, 1-Methyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide **679427-84-0P**, 1-Methyl-5-[(2R)-2-[[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]propyl]-N-(4-chlorobenzyl)-1H-indole-2-carboxamide **679427-85-1P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-(2-methoxybenzyl)-1H-indole-2-carboxamide **679427-86-2P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-(2,6-dimethoxybenzyl)-1H-indole-2-carboxamide **679427-87-3P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-(2-ethoxybenzyl)-1H-indole-2-carboxamide **679427-88-4P**, 5-[(2R)-2-[[(2R)-2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethyl]amino]butyl]-N-benzyl-1H-indole-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(β2 adrenergic receptor agonist; preparation of indolecarboxamides as β2 adrenergic receptor agonists)

ALL ANSWERS HAVE BEEN SCANNED

=> log y
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	1.31	324.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.39

STN INTERNATIONAL LOGOFF AT 11:34:57 ON 15 JUN 2004